CBL and neoplasm: Importantly, the synthetic peptide PVILLISFLI disrupted the PrP/c-CBL/IGF-1R combination in vitro and in vivo, thus reducing cancer cell autophagy and tumor aggressiveness (Li H. et al., 2022).